New Sidney Altman building officially opens at Babraham Research Campus
BioMed Realty UK has today officially opened the Sidney Altman Building at the Babraham Research Campus, unveiling a state-of-the-art facility designed for the next generation of life science innovation.
Game-changing accelerator which has helped life science start-ups raise £120m welcomes new cohort
Six exciting early-stage ventures secure coveted spots on Babraham Research Campus’ Accelerate@Babraham pre-seed company support programme.
Babraham Research Campus Ltd appoints Dr Rich Ferrie as Chief Executive Officer
Babraham Research Campus Ltd (BRCL), which is responsible for the development and management of Babraham Research Campus, is delighted to announce the appointment of Dr Rich Ferrie to the role of Chief Executive Officer.
Accelerate@Babraham applications now open
Starting something new is hard – particularly within the fast-moving life science sector.
Babraham Research Campus launches Growth Office Hours to strengthen wraparound support for LiveLabs companies
Babraham Research Campus is delighted to announce the launch of its Growth Office Hours, a new initiative designed to enhance the wraparound support available to companies within LiveLabs.
Forth Therapeutics: From LiveLabs to their own space at Babraham
Forth Therapeutics: From LiveLabs to their own space at Babraham
Accelerate@Babraham 2025 announces new cohort
Five new ventures secure the chance to be part of Babraham Research Campus - a leading location for early-stage life science start-ups.
Applications are now open for Accelerate@Babraham
Your opportunity to be part of one of the best Campus’ across the UK and Europe to start-up a life science venture.
Babraham Research Campus’ £3.15bn life science ecosystem soars
New report reveals how groundbreaking research at the Campus is delivering major gains for UK economic growth and job creation.
Babraham Research Campus Ltd appoints Dr Louise Jopling as Chief Scientific & Innovation Officer
Cambridge, UK, 12th November 2024: Babraham Research Campus Ltd, which is responsible for the development and management of Babraham Research Campus is delighted to announce the appointment of Dr Louise Jopling to the newly created role of Chief Scientific & Innovation Officer.
Applications are now open for Accelerate@Babraham
The programme, which each year offers five early-stage life science start-ups the chance to join the Babraham Research Campus community, brings to bear an unrivalled network of experts, mentors, investors, data-driven business support, lab space and funding to equip new enterprises with the skills, confidence, connections to enable success.
Babraham Research Campus announces new Board Appointment
Babraham Research Campus Ltd (BRC), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to welcome Charlie Foreman to the Board as non-executive director.
Accelerate@Babraham 2023 cohort revealed
Accelerate@Babraham, the Babraham Research Campus’ programme supporting early-stage life science ventures, announces new cohort
Winners of Accelerate@Babraham competition announced
Five promising early-stage life science ventures are beginning the next steps of their entrepreneurial adventure at one of the most successful locations for life science start-ups in Europe, the Babraham Research Campus, Cambridge.
All (name) change at the Babraham Research Campus
Babraham Bioscience Technologies Ltd, which manages and develops the Babraham Research Campus on behalf of its shareholders - BBSRC and the Babraham Institute – is now known as Babraham Research Campus Ltd.
Transine Therapeutics appoints industry veteran Jan Thirkettle PhD as CEO
Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, today announced the appointment of Jan Thirkettle, PhD as its Chief Executive Officer.
Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs
New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression.
The Babraham Research Campus sets out its vision and ambition for its future
The Babraham Research Campus vision is to be one of the best places in the world for discovery bioscience research and innovation; a leading sustainable ecosystem to start, nurture, scale and grow bioscience business.
Applications invited for Accelerate@Babraham life science start-up competition
Accelerate@Babraham, the bio-entrepreneurial incubator initiative founded and developed by the Babraham Research Campus - supported by key industry and investor organisations - opens applications for its 2021/22 cohort today.
Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study
Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research.
Alchemab raises £60 million in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
Babraham Research Campus announces new Board Chair Appointment
Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to confirm Jo Parfrey as the new BBT Board Chair.
Kidney Research UK confirmed as new strategic partner to the Babraham Research Campus Accelerate@Babraham initiative
The Babraham Research Campus is delighted to welcome the charity Kidney Research UK as the latest organisation to pledge strategic and financial support to its Accelerate@Babraham initiative. The additional funding boosts the ability of the Campus to continue to support and sustain innovation in early science concepts and nurture new life science companies across the Cambridge cluster.
Babraham Bioscience Technologies welcomes three new board members
Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus, is pleased to welcome three new members to its board.
Paediatric HealthTech wins Accelerate@Babraham with AstraZeneca Start-up Pitching Competition to secure £10,000
The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups - ArkVax, Paediatric HealthTech, ConcR and Stroma Biosciences - went head-to-head yesterday (Weds); competing for £10,000 additional funding generously donated by CMS Ventures in the Accelerate@Babraham with AstraZeneca: Start-up Pitching Competition.